Search

The article presents information about the financial statement of NPS Pharmaceuticals Inc. for the second quarter of 2012. It reported its net income of 7.4 million U.S. dollars for the second quarter of 2012 as compared to a net loss of 6.1 million U.S. dollars for the second quarter of 2011. Its cash and investments totaled to 110.4 million U.S. dollars.

The article offers information on the findings of placebo controlled phase three Replace study which was conducted by NPS Pharmaceuticals Inc. to evaluate the efficacy of the drug, Natpara in treatment of hypoparathyroidism in adults. The results were discusses with the help of oral and poster presentations at recently held the ENDO 2012 annual meeting of the Endocrine Society in Houston, Texas.

The article offers information on the results of clinical trials which was presented by NPS Pharmaceuticals Inc. at the Digestive Disease Week (DDW) meeting held in San Diego from May 19-22, 2012 to demonstrate the efficacy of the drug, Gattex in treatment of short bowel syndrome (SBS). The positive results related with the study were presented with the help of poster presentation.

The article informs that NPS Pharmaceuticals Inc. has released its financial results for the 1st quarter of 2012. It further informs that the company will be presenting on Natpara, a recombinant human parathyroid hormone, at the annual meeting of The Endocrine Society in June 2012. It mentions that the company will be hosting a conference call to discuss the financial results.

The article informs that NPS Pharmaceuticals Inc. will join the National Organization for Rare Disorders (NORD) Inc. on February 29, 2012 to observe World Rare Disease Day. National Institutes of Health (NIH) reports that 7,000 rare diseases are affecting millions of Americans while Food and Drug approved treatments are available only for 200 such diseases. It mentions that World Rare Disease Day, launched in Europe, is sponsored by NORD in the U.S.

The article provides information on the financial results of NPS Pharmaceuticals Inc. for the fourth quarter and full year ended December 31, 2011. The company reported a net loss of 8.6 million U.S. dollars for the fourth quarter of 2011 and a net loss of 36.3 million dollars for the full year 2011. Research & Development (R&D) expenses were 21.6 million U.S. dollars for the fourth quarter of 2011 and R&D expenses were 73.8 million dollars for the full year of 2011.

The article reports on the results of the pivotal Phase 3 REPLACE study of NPSP558 in hypoparathyroidism by NPS Pharmaceuticals Inc. It notes that NPSP558 is the company's bioengineered replica of human parathyroid hormone for the treatment of hypoparathyroidism. It adds that the REPLACE study has shown positive results, which expect to file for Food and Drug Administration (FDA) approval of the drug in 2012.

The article reports on the financial statements of Bedminster, New Jersey-based NPS Pharmaceuticals Inc. for the third quarter of 2011. It says that the company achieved a net loss of 12.3 million dollars or 0.14 dollar per diluted share. It notes the increase of NPS Pharmaceuticals' cash and investments from 133.8 million dollars on December 31, 2010 to 189.6 million dollars on September 30, 2011.

The article reports on the result of an open-label study on the safety and durability of GATTEX (teduglutide) in treating short term bowel syndrome in adults. NPS Pharmaceutical Inc. announced that GATTEX was associated with achieving and maintaining clinically meaningful reductions in parenteral nutrition (PN) and intravenous (IV) fluid volume in adult subjects with short bowel syndrome. The study found that 91% of subjects responded to 12 months of GATTEX treatment in the trial.

The article offers information on the presentation to be given by NPS Pharmaceuticals Inc. concerning hypoparathyroidism at the 2011 Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in San Diego, California on September 16-20, 2011.

The article reports the result of the Phase 3 study by NPS Pharmaceuticals Inc. on the efficacy of its Gattex (r) (teduglutide) drug in treating short bowel syndrome (SBS) and intestinal failure. Presented at a conference in Chicago, Illinois, the result states that Gattex reduces parenteral support (PS) volume in patients by an average of 4.4 liter weekly and their mean body weight remained unchanged. The company is expecting to file for its approval at U.S. Food and Drug Administration (FDA).

The article presents the first quarter financial performance in 2011 of the NPS Pharmaceuticals Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders in Bedminster, New Jersey. It shows the company's 9.2 million dollar net loss in the first quarter. However, chief executive officer (CEO) Francois Nader states that the success of its equity offering gives them the financial flexibility to deliver number of key milestones.

The article reports that NPS Pharmaceuticals Inc., a specialty pharmaceutical company that develops innovative treatments for rare gastrointestinal and endocrine disorders, will join the National Organization for Rare Disorders Inc. (NORD) for the World Disease Day on February 28, 2011. It says that NPS supports the Rare Disease Day to raise attention to rare diseases as an important public health concern worldwide. It adds that NPS focuses on short bowel syndrome (SBS) and hypoparathyroidism.

The article informs that the pharmaceutical firm developing therapeutics for rare gastrointestinal and endocrine disorders NPS Pharmaceuticals Inc. has received a communication from the U.S. Food & Drug Administration (FDA) extending the Prescription Drug User Fee Act (PDUFA) action date for its new drug application(NDA) for the product "Gattex," a teduglutide. It informs that Gattex is recombinant analog of human glucagon-like peptide 2.

The article presents information on an announcement made by NPS Pharmaceuticals Inc. regarding the notice from the U.S. Food & Drug Administration (FDA) to discuss its New Drug Application (NDA) for the approval of drug Gattex at the Gastrointestinal Drugs Advisory Committee meeting to be held on October 16, 2012. The proposed idea for Gattex is the treatment of patients with short bowel syndrome.

The article informs that the U.S. Food & Drug Administration (FDA) has notified the NPS Pharmaceuticals Inc. that its New Drug Application (NDA) for Gattex will be discussed at the Gastrointestinal Drugs Advisory Committee meeting to be held on October 16, 2012. Gattex is a recombinant analog of human glucagon-like peptide 2. The Gastrointestinal Drugs Advisory Committee reviews data relating the safety and effectiveness of investigational human drug products.

The article presents information on an announcement made by NPS Pharmaceuticals Inc. regarding the extension of action date for the approval of its New Drug Application (NDA) for peptide Gattex by three months to December 30, 2012. The U.S. Food & Drug Administration (FDA) extended the action date to provide time for a full review of the submission. The proposed trait of Gattex is the treatment of the patients with short bowel syndrome.

The article provides information on the Oley Foundation's second annual Home Parenteral Nutrition (HPN) Awareness Week being held from August 5-11, 2012 supported by NPS Pharmaceuticals Inc. It informs HPN is an intravenous fluid for patients who are unable to receive enough nutrients from a normal diet. It further informs that HPN patients are encouraged to share their stories with local media, upload videos on YOUTUBE or blog about their experiences.

The article offers information on ENDO 2012, the annual meeting of The Endocrine Society to be held in Houston, Texas on June 23-26, 2012 where NPS Pharmaceuticals Inc. will be presenting three abstracts with respect to the phase III REPLACE study of its product Natpara in hypoparathyroidism.

The article presents information on an announcement made by the pharmaceutical company NPS Pharmaceuticals Inc. focusing on treatment for gastrointestinal and endocrine disorders, on the success in the use of Gattex therapy that use teduglutide. The treatment can be used in the case of parenteral nutrition and intravenous fluids in short bowel syndrome of adults.

The article announces that NPS Pharmaceuticals Inc. has appointed Georges Gemayel, President of Altus Pharmaceuticals Inc., to its board of directors.

The article reports on the submission by NPS Pharmaceuticals, Inc. of the chemistry, manufacturing and controls (CMC) portion of its new drug application (NDA) for GATTEX(r) to the U.S. Food and Drug Administration (FDA). It states that the company develops GATTEX(r) to treat adults with short bowel syndrome (SBS). NPS Pharmaceuticals president Francois Nader comments on the submission.

The article focuses on the completion of the Phase 3 REPLACE study of NPS Pharmaceuticals Inc. for its NPSP558, a bioengineered form of human parathyroid hormone 1-84. REPLACE was a double-blind placebo-controlled study, which assesses the use of NPSP558 as hormone replacement therapy in adult patients with hypoparathyroidism. Moreover, results from an investigator-initiated Phase 2 study showed that NPSP558 treatment reduces supplemental calcium and 1,25-dihydroxyvitamin D requirements.

The article offers information on a teleconference of NPS Pharmaceuticals Inc. to be held on August 1, 2012 for disclosing its second quarter 2012 financial statement.

The article offers information on the Canaccord Genuity Annual Growth Conference to be held in Boston, Massachusetts on August 14, 2012 and the Wedbush Securities Life Sciences Management Access Conference to be held in New York on August 15, 2012 attended by NPS Pharmaceuticals Inc.

The article informs that NPS Pharmaceuticals Inc. has licensed its cinacalcet to Amgen Inc. for the treatment of hyperparathyroidism. It mentions that NPS will receive a payment of worth 25 million dollars in exchange for its rights to receive royalties. It further informs that the company has developed drugs for the treatment of hypoparathyroidism and short bowel syndrome.

The article previews the web site hypoparathyroidism, located at www.hypoparathyroidism.com from the NPS Pharmaceuticals Inc.

The article informs that NPS Pharmaceuticals Inc. in association with Hypoparathyroidism Association will support World Hypoparathyroidism Awareness Day. It further informs that a patient conference will be conducted from June 7-9, 2012 in Rockville, Maryland. It mentions the complications of hypoparathyroidism which include muscle spasms, tetany and depression.

The article informs that the Jefferies 2012 Global Healthcare Conference to be held on June 4, 2012 in New York will feature a presentation by NPS Pharmaceuticals Inc.

The article informs that NPS Pharmaceuticals Inc. has been recognized by the periodical "NJBIZ" as one of the 100 best places to work in New Jersey in 2012. The program recognizes companies that provide the best work environment throughout New Jersey. 52 small or medium companies with 15-249 employees were recognized, including NPS, as were 48 large companies with 250 or more employees. NPS is a biopharmaceutical company focused on bringing orphan drugs to patients with rare disorders.

The article provides information on a conference call to be hosted by NPS Pharmaceuticals Inc. on May 3, 2012 to discuss its first quarter 2012 financial results.

The article offers information on Needham and Co. LLC 11th Healthcare Conference to be held in New York City on April 3-4, 2012 where NPS Pharmaceuticals Inc. will be delivering a presentation.

The article offers information related to an announcement made by NPS Pharmaceuticals Inc. regarding reporting of its financial results for 2011 on February 15, 2012. The company is also hosting a conference call and webcast in order to discuss its financial results. It is a biopharmaceutical company which develop orphandrugs for patients suffering from rare disorders.

The article reports that NPS Pharmaceuticals Inc. will present at the 8th Annual Healthcare Conference of the Lazard Capital Markets LLC to be held in New York City in November 15, 2011. It states that NPS is an outsourcing-based development company focused on bringing biopharmaceuticals to patients with rare disorders. It mentions that NPS is advancing 2 Phase 3 registration programs, GATTEX in adult short bowel syndrome (SBS), and NPSP558 in hypoparathyroidism.

The article reports on the participation of NPS Pharmaceuticals Inc. in the NASDAQ opening bell ceremony. It mentions that president of specialty pharmaceutical company, Francois Nader with senior management and directors will ring the NASDAQ Stock Market bell .It states that the 25th anniversary of the company is celebrated in the bell ringing ceremony on November 7, 2011.

The article reports that NPS Pharmaceuticals Inc. in Bedminster, New Jersey will announce its 2011 third quarter financial revenues on November 3, 2011. It states that a a webcast and a conference call will follow after the announcement which will be available at the NPS website. It notes that NPS Pharmaceuticals is an outsourcing-based development company that concentrates on bringing biopharmaceuticals to patients with rare disorders.

The article announces that biopharmaceutical company NPS Pharmaceutical Inc. in Bedminster, New Jersey is to host a conference call at 2:15 Eastern Time (ET) on October 31, 2011 to discuss GATTEX (r) (teduglutide) data reported at the American College of Gastroenterology Annual Scientific Meeting.

The article reports on the financial results of Bedminster, New Jersey-based NPS Pharmaceuticals Inc. in the first quarter of 2011 to be presented on May 3 which will be followed by a conference call and webcast. A live audio of the conference call and the webcast will be available over the Internet and can be accessed through the NPS website http://www.npsp.com/events. Other details of the conference call and webcast is noted.

The article announces that NPS Pharmaceuticals Inc. will present at the Deutsche Bank Securities Inc. 36th Annual Health Care Conference in Boston, Massachusetts on May 4, 2011. It states that the presentation will be available as a live webcast with a replay available three hours after the presentation has concluded. It mentions that NPS Pharmaceuticals is an outsourcing-based development company focusing on bringing biopharmaceuticals to patients with rare disorders.

The article announces that NPS Pharmaceuticals Inc. will present in a live webcast at the 10th Annual Needham Conference 2011 in New York on April 6.

The article informs that NPS Pharmaceuticals Inc. (NPS) has announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price of 9.00 dollars per share. NPS has granted the underwriters a 30-day option to purchase up to an aggregate of 1,650,000 additional shares of common stock.

The article focuses on NPS Pharmaceuticals Inc. which will present a live webcast at the Barclays Capital 2011 Global Healthcare Conference on March 15, 2011 in Miami, Florida.

The article focuses on the launch of the interactive website ShortBowelSupport.com of NPS Pharmaceuticals Inc. (NPSP). Joan Bishop of The Oley Foundation says that the launch of the website provides hope for patients with short bowel syndrome (SBS) because it gives opportunities to patients to share their experiences. Roger Garceau of NPS Pharmaceuticals adds that they are proud to launch the website because it is a part of their commitment to patients with SBS.

The article offers information on the Seventh Annual JMP Securities Healthcare Conference to be held in New York on July 12, 2012 in NPS Pharmaceuticals Inc. will give a business presentation.

The article presents information on an announcement made by NPS Pharmaceuticals Inc. to participate in the Leerink Swann Global Healthcare Conference to be held in New York City on February 16, 2012. The company will also participate in the 14th Annual Biotechnology Industry Organization (BIO) Chief Executive Officers (CEO) & Investor Conference to be held in New York City on February 13, 2012. Webcast of both presentations will be available on the company's website.

The article offers information related to presentation being held by NPS Pharmaceuticals Inc. at the 30th Annual J.P. Morgan Healthcare Conference to be held in San Francisco, California on January 12, 2012.

The article offers information on the presentation by NPS Pharmaceuticals Inc. at the Jefferies & Co. Inc.'s 2011 Global Healthcare Conference to be held in New York City on June 8, 2011.

The article reports on the public offering of common stock by NPS Pharmaceuticals Inc., an outsourcing-based development company focused on bringing biopharmaceuticals to patients with rare disorders. It states NPS has commenced an underwritten public offering of 9,000,000 shares of its common stock pursuant to an effective shelf registration statement. It reports on Citigroup Global Markets Inc. and Leerink Swann LLC, which are acting as joint book-running managers for the offering.

The article offers information on analyst and investor briefing, hosted by NPS Pharmaceuticals Inc., to be held in New York on May 11, 2011.

The article reports on the announcement from the biopharmaceutical firm NPS Pharmaceuticals Inc. that it had closed its public offering of common stock in Bedminster, New Jersey. It mentions that the company had underwritten 12,650,000 shares of common stock, including 1,650,000 shares for exercise of an option granted to underwriters. It notes that Citigroup Inc. and Leerink Swann LLC had acted as the stock managers.